.svg)
Oral dosage forms have always been designed around safety, efficacy, and stability. Increasingly, however, another parameter is influencing product success: patient acceptability.
This is a significant challenge, as unpleasant taste is common across drug molecules. A 2024 review covering 155 active pharmaceutical ingredients (APIs) identified taste masking as a major formulation challenge, reinforcing that bitterness is a widespread characteristic rather than an exception. A 2025 scoping review similarly found repeated links between poor-tasting pediatric medicines, medication refusal, acceptability issues, and adherence barriers.
Oral dosage forms are evolving. Oral thin films, orally disintegrating systems, multiparticulates, and personalised medicines are becoming more prevalent. Formulation scientists must address taste without compromising dissolution, stability, bioavailability, or therapeutic performance. Traditional approaches such as flavours and polymer coatings remain valuable, but recent advances in nanotechnology, smart polymers, and additive manufacturing are expanding what taste masking technology can achieve for patient-centric oral drug delivery.
Effective taste masking in pharmaceuticals is far more complex than adding flavours or sweeteners. Many APIs interact directly with bitter taste receptors within seconds of oral administration. Formulation strategies must minimise this interaction while still ensuring appropriate drug release.
This challenge is particularly relevant across paediatric and geriatric therapies. Children are generally more sensitive to bitter tastes, while older patients often experience swallowing difficulties or rely on dosage forms that dissolve in the oral cavity. For oral thin films and orally disintegrating products, where the API is intentionally released in the mouth, formulation design becomes even more demanding.
Every molecule presents a different set of formulation variables, including solubility, dose strength, bitterness threshold, particle size, release profile, and target patient population. A coating strategy that works for one API may negatively affect dissolution or bioavailability in another. This is why no single taste masking technology serves as a universal solution, making molecule-specific pharmaceutical formulation development essential.
Conventional pharmaceutical formulation development continues to rely on several established taste masking strategies that combine scalability with regulatory familiarity.
Coating technologies create a physical barrier between the API and taste receptors through polymer films, coated pellets, granules, or microencapsulation. These systems effectively delay dissolution in saliva but require careful optimisation to avoid altering release kinetics.
Complexation and encapsulation techniques reduce bitterness by temporarily binding APIs to carriers such as cyclodextrins or ion-exchange resins. This limits the amount of free drug present in the oral cavity, while allowing release under gastrointestinal conditions.
Flavours, sweeteners, and organoleptic modifiers remain widely used to improve overall sensory perception. Although cost-effective and easy to incorporate, they typically complement rather than replace structural taste masking approaches for highly bitter APIs.
Recent innovations are shifting taste masking technology from simple sensory modification towards engineered control of API exposure and release.
Nanocarrier systems, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanoemulsions, and nanogels, are emerging as promising solutions for highly bitter molecules. Instead of merely covering bitterness, these carriers minimise direct interaction between APIs and taste receptors while maintaining drug solubility and controlled release. This dual functionality makes nanotechnology particularly valuable for poorly soluble compounds where conventional approaches may compromise bioavailability.
Functional polymers are also transforming taste masking in pharmaceuticals. pH-responsive and ion-sensitive coatings remain stable during the brief period of oral exposure before releasing the drug under gastrointestinal conditions. Better understanding of polymer-drug interactions is allowing formulation scientists to design systems based on predictable molecular behaviour rather than trial-and-error optimisation.
3D printing introduces new possibilities for pharmaceutical formulation development by enabling layered structures, compartmentalised APIs, and customised oral dosage forms. Spatial localisation of bitter APIs within printed structures can reduce taste perception while supporting personalised dosing and controlled release, making additive manufacturing an important area of future formulation research.
Emerging research increasingly approaches taste masking through the combined control of time, concentration, and perception rather than relying solely on excipient selection. This strategy is particularly relevant for oral thin films and orally disintegrating dosage forms, where managing API exposure during the first few seconds of administration is essential for improving patient acceptance.
As discussed in our blog on oral thin film manufacturing, advances in formulation science are enabling patient-friendly dosage forms without compromising scalability or therapeutic performance.
As pharmaceutical innovation shifts towards patient-centric products, taste masking technology is becoming a strategic formulation capability rather than a finishing step.
Effective taste masking improves adherence across pediatric, geriatric, and swallowing-impaired populations while supporting the adoption of oral thin films and other innovative oral dosage forms. Because these formulations dissolve directly in the mouth, successful product development depends on balancing rapid administration with acceptable sensory performance.
From a commercial perspective, robust taste masking in pharmaceuticals enables differentiated products that combine convenience, compliance, and therapeutic efficacy. It therefore contributes not only to better patient experience but also to stronger product positioning in increasingly competitive oral drug delivery markets.
Future taste masking technology is expected to integrate advanced materials, digital formulation tools, and personalised manufacturing approaches. Researchers are exploring natural polymers, sustainable excipients, and functional materials capable of delivering improved palatability alongside predictable release behaviour.
Another important shift is the integration of taste masking into early-stage pharmaceutical formulation development rather than treating it as a late-stage optimisation exercise. Evaluating API sensory characteristics alongside solubility, stability, and dosage-form selection enables more efficient development pathways and reduces formulation risk.
As oral drug delivery systems become increasingly patient-focused, pharmaceutical manufacturers require formulation partners with expertise spanning taste masking, polymer science, oral thin films, and advanced dosage-form development. Integrated formulation capabilities help transform complex molecules into commercially scalable, patient-friendly products while maintaining the performance, quality, and regulatory standards expected in global pharmaceutical markets.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
